Fortitude Family Office’s Cytek Biosciences CTKB Stock Holding History

Fortitude Family Office’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$509	Buy	+115	New	+$491	﹤0.01%	1974

Other funds holding CTKB

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office's CTKB Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 115 shares worth $509. The stake represents ﹤0.01% of the portfolio and ranks #1974 among its holdings.

18 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Fortitude Family Office held 115 shares of Cytek Biosciences worth $509 as of Q2 2026.
Cytek Biosciences was a new Fortitude Family Office position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1974 holding.
18 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.